subscribeSubscribe
Glenmark partners with Pfizer to launch abrocitinib in India

Glenmark partners with Pfizer to launch abrocitinib in India
ECONOMIC TIMES
31 Jan 2024
Share Share
FDA Approves Pfizer`s Supplemental New Drug Application for CIBINQO

FDA Approves Pfizer`s Supplemental New Drug Application for CIBINQO
BUSINESSWIRE
10 Feb 2023
Share Share
2022 drug approvals: Biopharma delivered 37 new drugs

2022 drug approvals: Biopharma delivered 37 new drugs
Kevin Dunleavy FIERCE PHARMA
03 Jan 2023
Share Share
EMA backs restrictions on certain immune-regulating drugs

EMA backs restrictions on certain immune-regulating drugs
BIOPHARMADIVE
12 Nov 2022
Share Share
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC

JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
Catherine Eckford EUROPEANPHARMACEUTICALREVIEW
01 Nov 2022
Share Share
EMA limits use of JAK inhibitors for at-risk groups in wake of safety concerns

EMA limits use of JAK inhibitors for at-risk groups in wake of safety concerns
Nicole DeFeudis ENDPTS
29 Oct 2022
Share Share
NICE recommend’s use of Leo Pharma’s Adtralza

NICE recommend’s use of Leo Pharma’s Adtralza
John Pinching PHARMATIMES
07 Jul 2022
Share Share
Health Canada Approves Use of CIBINQO for Moderate-to-Severe Atopic Dermatitis

Health Canada Approves Use of CIBINQO for Moderate-to-Severe Atopic Dermatitis
BIOSPACE
04 Jul 2022
Share Share
NICE recommends dermatitis treatment for use in NHS England and Wales

NICE recommends dermatitis treatment for use in NHS England and Wales
PHARMAFILE
30 Jun 2022
Share Share
FDA offers a tardy green light to Pfizer`s JAK1 drug abrocitinib

FDA offers a tardy green light to Pfizer`s JAK1 drug abrocitinib
J. Carroll ENDPTS
15 Jan 2022
Share Share